Navigation Links
Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
Date:8/18/2010

NEW YORK, Aug. 18 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDSTD), a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").  Lonza Walkersville is a subsidiary of Lonza Group Ltd. (SIX: LONN), one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries and the largest cell therapy manufacturer in the world.

The Lonza Agreement provides Regenicin with the worldwide marketing rights to a proprietary tissue-engineered skin substitute technology intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.  Regenicin's management team intends to use its expertise, with the assistance of Lonza Walkersville, to further enhance its capabilities and seek approval by the U.S. Food and Drug Administration for commercial sale. Regenicin plans to seek marketing approval for this revolutionary product throughout the world under the brand name PermaDerm™.  

Pursuant to the Lonza Agreement, Lonza will retain exclusive manufacturing rights for PermaDerm™ products.  Additionally, a license to the patent rights and related key intellectual property comprising the technology, developed at the University of California, University of Colorado, the University of Cincinnati and Shriners Hospitals for Children, may be acquired by Regenicin if FDA approval is obtained.

Regenicin secured the initial financing through a combination of convertible loans and a private placement of its common stock with several major institutions and accredited investors. NewOak Capital, Inc. and Smith Point, Ltd. acted as co-placement agents.  

"We are excited to have secured the funds necessary to help us complete this licensing agreement with Lonza and to prepare to advance this important technology to commercialization.  We believe Regenicin is now poised to address a significant unmet medical need as PermaDerm™ is the only tissue-engineered skin prepared from a patient's own skin cells," Randall McCoy, Chief Executive Officer of Regenicin said.  "The technology combines cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components.  This model has been shown in preclinical studies to generate a functional skin barrier, which is an important step towards realizing the potential of regenerative medicine."

About Regenicin, Inc.

Regenicin, Inc. is a development stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in Little Falls, NJ. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
2. Resverlogix Completes Dosing for ASSERT Trial
3. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
4. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
5. Hendrick Construction Completes Oak Ridge National Laboratory Expansion
6. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
7. Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.
8. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
9. EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
10. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
11. Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2017)... ... 15, 2017 , ... The newest exhibition at the University ... experimentation and interdisciplinary collaboration. Feature Creep, a solo exhibition by Maximillian Lawrence, opens ... be held at EKG, located at 3600 Market Street in Philadelphia, on Thursday, ...
(Date:6/15/2017)... , ... June 15, 2017 , ... ... director for DuPont Biofuels, will be speaking at Bloomberg’s 2017 Sustainable Business ... join other leading environmental and sustainability officials on a panel titled “Developing a ...
(Date:6/14/2017)... (PRWEB) , ... June 14, 2017 , ... ... June 8th to discuss the initiative steered by the executive search firm, “Building ... Chairman of the Board of Directors of Foundation Medicine, led an open discussion ...
(Date:6/14/2017)... ... June 14, 2017 , ... Graphite Metallizing Corporation, the manufacturer ... appointed Andrew Ondish as Territory Sales Manager for New Jersey, Eastern Pennsylvania, Delaware, ... Engineering from Colorado School of Mines. With nearly thirty years of experience in ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):